Get In Touch
Have any questions or comments about the content you see on this page?
October 1, 2020
The COVID-19 pandemic has once again ignited the debate over the sustainability of healthcare systems and the need for forward-looking solutions more acutely than ever. At a time when many U.S. and European biotech companies are emerging and innovating, we remain committed to our mission and values. For Alnylam, these are reflected in the Patient Access Philosophy we pledged three years ago, a promise to put patients first, continue our focus on innovation and be accountable to patients, and their families. We continue to live and operate by these values.
That is why our CEO, John Maraganore, has joined almost 70 leaders of European and U.S. life science and biotech companies, along with investors and other stakeholders, to sign a “New European Biotech Social Pact with Europe and Patients.”
The European Pact builds on Alnylam’s own pledge, encouraging biotech companies to be a force for good in partnering with European authorities, citizens and patients in creating a system where scientific investment ultimately yields effective, affordable and accessible therapeutics for future generations.
Our industry is unique. We save, extend and enhance lives by alleviating the burden of disease. Our mission is to change the course of each individual’s life for the better. To achieve this, we acknowledge that we have a moral obligation to develop the best medicines and strive to ensure that every person who may benefit has access to them. And we need to ensure that we act with the highest integrity and corporate responsibility- always prioritizing the interests of patients. - New European Biotech Social Pact with Europe and Patients
We are acutely aware that actions taken as a global, commercial company impact real, human lives. We firmly believe that we will only do well by doing good. Working alongside our partners, peers and patient communities, the European Social Pact aims to initiate much-needed dialogue between the industry innovators, healthcare authorities and other stakeholders, so that we can come together and find sustainable solutions that work for all parties. It’s only by doing this that we will be able to fulfill our obligations to patients by providing solutions for innovative pricing, reimbursement and access, and to government on intellectual property and regulatory incentives.
We hope others will join us as we re-commit to fulfilling our obligations to our key communities and renew trust and confidence in how we deliver on our mission. You can learn more about the New European Biotech Social Pact here.
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.Proceed to Site